Arrowstreet Capital Limited Partnership Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Arrowstreet Capital Limited Partnership raised its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 123.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 222,520 shares of the company's stock after purchasing an additional 122,823 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 0.59% of Entrada Therapeutics worth $3,847,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TRDA. Vanguard Group Inc. boosted its holdings in Entrada Therapeutics by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock worth $25,317,000 after buying an additional 241,052 shares during the period. Geode Capital Management LLC lifted its position in shares of Entrada Therapeutics by 8.8% during the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock worth $9,214,000 after acquiring an additional 46,512 shares in the last quarter. State Street Corp boosted its holdings in shares of Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company's stock worth $7,504,000 after acquiring an additional 24,385 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Entrada Therapeutics by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company's stock valued at $3,408,000 after purchasing an additional 11,143 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Entrada Therapeutics by 17.7% during the 4th quarter. American Century Companies Inc. now owns 59,710 shares of the company's stock valued at $1,032,000 after purchasing an additional 8,985 shares during the period. Institutional investors own 86.39% of the company's stock.

Remove Ads

Entrada Therapeutics Stock Down 0.3 %

Shares of TRDA stock traded down $0.02 on Monday, reaching $7.88. The company's stock had a trading volume of 5,715 shares, compared to its average volume of 127,324. The company has a market capitalization of $296.25 million, a P/E ratio of 4.96 and a beta of 0.04. Entrada Therapeutics, Inc. has a 12-month low of $7.10 and a 12-month high of $21.79. The stock's 50 day simple moving average is $10.81 and its 200-day simple moving average is $14.87.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.66) by $0.69. The company had revenue of $12.25 million during the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. Research analysts expect that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Entrada Therapeutics in a report on Monday, March 31st.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.